„The future is here! The next generation of AAV vector as a foundation of cell and gene therapeutics of the future“

Associate Professor Lisowski received his PhD from Weill Cornell University in New York for studies related to the development of lentiviral vectors for the treatment of β-thalassemia and completed his postdoctoral training at Stanford University School of Medicine where he mastered design, production, and functional validation of novel bioengineered vectors based on adeno-associated virus (AAV). He developed the first bioengineered rAAV to enter clinical evaluation. In 2012, he was recruited by the Salk Institute for Biological Studies to oversee their Gene Transfer, Targeting and Therapeutic (GT3) facility. In 2015, he was recruited by the University of Sydney / Children’s Medical Research Institute (CMRI) to establish his independent research team, Translational Vectorology Research Unit (TVRU), and to establish and manage the Vector and Genome Engineering Facility (VGEF). His research concentrates on the studies of AAV biology and vectorology, and development of novel bioengineered AAV variants for clinical applications. In addition, his group specializes also in development and improvement of viral vector manufacturing technologies, including upstream production and downstream purification, with special interest in clinical vector manufacturing. His team is leading a number of gene therapy programs that aim to develop novel advanced therapeutics for paediatric genetic disorders affecting the CNS, lungs, liver and other organs.